Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
CureVac N.V. (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a…
The Daily Biotech Pulse: Third FDA Rejection For Verrica’s Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva’s Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours.
CureVac To Partner With myNEO To Identify Novel Antigen Targets For mRNA-Based Cancer Vaccine Development
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
How To Attend CureVac Q4 2021 Earnings Conference Call
CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results.
How to Attend CureVac (CVAC) Conference Call
Follow this link to access the live webcast.
UPDATE: CureVac, GlaxoSmithKline Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study (Body Of This Headline Contains Contents Of Press Release)
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
- Demonstrated neutralizing capacity against the Omicron variant in vaccinated
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for…
CureVac – GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline…